Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

Fig. 1

Expression of PD-L1 and PD-1 in breast tumors. FACS and immunohistochemistry (IHC) analysis of a E0771 and b EMT-6 cells grown in vitro to determine whether PD-L1 is constitutively expressed and/or is inducible by IFNγ treatment. PD-1, programmed death 1, PD-L1 programmed death-1 ligand 1

Back to article page
\